KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $21.39 $29.07 Friday, 26th Apr 2024 ARWR stock ended at $22.12. This is 1.14% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 2.95% from a day low at $21.72 to a day high of $22.36.
90 days $21.39 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Mar 22, 2023 $24.54 $24.89 $23.68 $23.72 1 067 593
Mar 21, 2023 $25.10 $25.50 $24.56 $24.60 969 774
Mar 20, 2023 $24.39 $25.87 $24.33 $25.06 1 518 345
Mar 17, 2023 $24.34 $24.39 $23.09 $24.30 2 395 055
Mar 16, 2023 $25.12 $25.26 $24.19 $24.44 2 229 004
Mar 15, 2023 $26.76 $26.76 $24.75 $25.32 2 017 813
Mar 14, 2023 $26.99 $27.87 $26.25 $26.56 1 388 345
Mar 13, 2023 $26.04 $26.93 $25.70 $26.42 2 752 722
Mar 10, 2023 $27.59 $27.68 $25.54 $26.31 2 061 569
Mar 09, 2023 $29.68 $29.90 $27.60 $27.73 1 738 226
Mar 08, 2023 $30.50 $30.70 $29.20 $29.66 1 170 799
Mar 07, 2023 $30.62 $31.07 $30.22 $30.50 848 460
Mar 06, 2023 $32.44 $32.68 $30.33 $30.79 1 288 107
Mar 03, 2023 $32.57 $33.15 $32.16 $32.35 1 172 782
Mar 02, 2023 $32.28 $32.84 $31.51 $32.43 1 083 934
Mar 01, 2023 $32.45 $32.84 $32.40 $32.66 1 125 980
Feb 28, 2023 $32.45 $33.12 $32.28 $32.30 924 508
Feb 27, 2023 $33.05 $33.17 $32.34 $32.60 682 301
Feb 24, 2023 $32.10 $32.85 $32.10 $32.63 866 001
Feb 23, 2023 $32.90 $33.07 $32.52 $32.75 665 204
Feb 22, 2023 $31.83 $32.95 $31.78 $32.85 772 404
Feb 21, 2023 $33.00 $33.28 $31.29 $31.77 897 529
Feb 17, 2023 $33.07 $33.86 $32.50 $33.75 584 136
Feb 16, 2023 $33.36 $33.80 $32.94 $32.97 615 584
Feb 15, 2023 $33.23 $34.08 $32.76 $34.05 626 675
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT